Last reviewed · How we verify
Syfovre™
Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina.
Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina. Used for Geographic atrophy secondary to age-related macular degeneration (AMD).
At a glance
| Generic name | Syfovre™ |
|---|---|
| Also known as | Pegcetacoplan injection |
| Sponsor | Hoffmann-La Roche |
| Drug class | Anti-VEGF aptamer |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Syfovre (pegcetacoplan) is a 40-nucleotide RNA aptamer that directly binds to VEGF-A, preventing its interaction with VEGF receptors on endothelial cells. By blocking VEGF signaling, it reduces pathological neovascularization and vascular permeability in the eye. It is administered via intravitreal injection directly into the eye to achieve high local concentrations while minimizing systemic exposure.
Approved indications
- Geographic atrophy secondary to age-related macular degeneration (AMD)
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular inflammation
- Retinal pigment epithelium tear
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Syfovre™ CI brief — competitive landscape report
- Syfovre™ updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI